5 Best Regional Bank Stocks To Buy For 2015

5 Best Regional Bank Stocks To Buy For 2015: Auxilium Pharmaceuticals Inc.(AUXL)

Auxilium Pharmaceuticals, Inc. operates as a specialty biopharmaceutical company primarily in the United States. It focuses on developing and marketing products to urologists, endocrinologists, primary care physicians, hand surgeons, and rheumatologists, as well as to orthopedic, general, and plastic surgeons. The company markets XIAFLEX (collagenase clostridium histolyticum), an injectable collagenase enzyme for the treatment of adult Dupuytren?s contracture; and Testim, a topical 1% testosterone gel for the treatment of hypogonadism. The company?s clinical development products include XIAFLEX that is in Phase III clinical trials for the treatment of Peyronie?s disease, as well as in Phase II clinical trials for the treatment of Adhesive Capsulitis. In addition, it has rights to develop other products for the treatment of pain, urologic disease, and hormone replacement using its transmucosal film delivery system. The company has a strategic alliance with Asahi Kasei Ph ar ma Corporation for the development, commercialization, and supply of XIAFLEX, a biologic for the treatment of Dupuytren?s contracture and Peyronie?s disease. Auxilium Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Malvern, Pennsylvania.

Advisors' Opinion:

• [By Peter Graham]

  Reuters quoted Wells Fargo analyst Matthew Andrews as saying in a a note that the label expansion was "incrementally positive." It should be added that last fall, VIVUS, Inc sold the rights to sell Stendra in the United States and Canada to Auxilium Pharmaceuticals, Inc (NASDAQ: AUXL) in a deal that could be worth $300 million -depending on royalty payments.

• [By Roberto Pedone]

  One potential earnings short-squeeze candidate is biotechnology player Auxilium Pharmaceuticals (AUXL), which is set to release numbers on Thursday before the market open. Wall Street analysts, on average, expect Auxilium ! Pharmaceuticals to report revenue of $91.43 million on a loss of 3 cents per share.

  During the last quarter, this company reported revenue of $66.2 million and GAAP reported sales were 10% lower than the prior-year quarter's $73.6 million. Also during the last quarter, this company reported non-GAAP EPS of -12 cents per share and GAAP EPS of -17 cents per share.

  The current short interest as a percentage of the float for Auxilium Pharmaceuticals is pretty high at 11.1%. That means that out of the 39.84 million shares in the tradable float, 5.14 million shares are sold short by the bears. This is a decent short interest on a stock with a relatively low tradable float. If the bulls get the earnings news they're looking for, then shares of AUXL could easily rip higher post-earnings as the bears rush to cover some of their short bets.

  From a technical perspective, AUXL is currently trending above both its 50-day and 200-day moving averages, which is bullish. This stock has been uptrending strong for the last three months, with shares soaring higher from its low of $13.87 to its intraday high of $18.42 a share. During that uptrend, shares of AUXL have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of AUXL within range of triggering a major breakout trade post-earnings.

  If you're bullish on AUXL, then I would wait until after its report and look for long-biased trades if this stock manages to break out above some key overhead resistance levels at $18.50 to $19.60 a share with high volume. Look for volume on that move that registers near or above its three-month average action of 834,059 shares. If that breakout hits, then AUXL will set up

• [By Sean Williams]

  Also, the testosterone market is also glutted with competition and Aveed, even will likely have a hard time making any meaningful impact for Endo. AbbVie (NYSE: ABBV  ) recently reformulated its AndroGel testost! erone tre! atment into a more potent form at 1.62% and in 2011 received FDA approval after 82% of hypogonadal men achieved normal testosterone levels after 112 days. Also operating in the gel space is Auxilium Pharmaceuticals' (NASDAQ: AUXL  ) drug Testim, which achieved $455 million in sales in the first quarter. That figure actually represents a 23% year-over-year decline because of difficulties in gaining insurance coverage for the gel, but it's yet another hurdle for Aveed to jump over if it were to reach market.

• [By Jake L'Ecuyer]

  Auxilium Pharmaceuticals (NASDAQ: AUXL) was also up, gaining 12.11 percent to $21.67 following FDA approval of its Peyronie's disease treatment, Xiaflex.

source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/5-best-regional-bank-stocks-to-buy-for-2015-3.html